Vertex (VERX) Valuation Discount and 82.67% Earnings Growth Forecast Highlight Optimistic Sentiment

Vertex (VERX) remains unprofitable but is narrowing its losses at an average rate of 16.4% per year over the past five years. Looking ahead, the company’s annual revenue is expected to grow by 12.4% ...

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN; ORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuri ...